Because of the successful treatment of KIT expressing GISTs [53, 54] and because of the recent insight that KIT receptor activation through its ligand stem cell factor (SCF) stimulates growing of MCC cells in vitro [55], imatinib was assumed to be a promising therapeutic option for MCC. The gene discussed is KITLG; the disease is Merkel cell skin cancer.